Silver Book Fact

An antibiotic stewardship program saved $17 million over 8 years

An antibiotic stewardship program saved a total of $17 million over 8 years, with antibiotic costs rising $1 million in the first year after discontinuation.

Standiford H, Chan S, Tripoli M, Weekes E, et al. Antimicrobial Stewardship at a Large Tertiary Care Academic Medical Center: Cost analysis, before, during, and after a 7-year program. Infect Control Hosp Epidemiol. 2015; 33(4): 338-345. https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/antimicrobial-stewardship-at-a-large-tertiary-care-academic-medical-center-cost-analysis-before-during-and-after-a-7year-program/95CB82200F2691F29FFEA701DBDF928E

Reference

Title
Antimicrobial Stewardship at a Large Tertiary Care Academic Medical Center: Cost analysis, before, during, and after a 7-year program
Publication
Infect Control Hosp Epidemiol
Publisher
University of Chicago Press
Publication Date
2015
Authors
Standiford H, Chan S, Tripoli M, Weekes E, et al
Volume & Issue
Volume 33, Issue 4
Pages
338-345
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • An antibiotic stewardship program saved $17 million over 8 years
    An antibiotic stewardship program saved a total of $17 million over 8 years, with antibiotic costs rising $1 million in the first year after discontinuation.  
  • Infection control program reduced hospital-acquired HAIs by > 1/3
    A multimodal infection control program reduced the rate of hospital-acquired HAIs by more than 1/3 and improved quality of care and patient outcomes.  
  • New antibacterial agents between 1983 and 2012
    Total number of new antibacterial agents is in decline  
  • Pre-surgery antibiotic use reduces 6-day mortality by 50% in elderly
    Effective pre-surgery antibiotic use can reduce 60-day mortality in the elderly by 50%.  
  • Negative value of antibiotics to drug companies
    The value of an antibiotic to a drug company is negative $50 million- compared to the positive value of $1 billion for a new musculoskeletal drug.